Real world evidence of palbociclib use in metastatic hormone positive HER negative metastatic breast cancer in Indian population

Background: Hormone positive, HER-2 negative metastatic breast cancer (HR+/HER2- MBC) had always been challenging to treat. With the addition of Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to the treatment armamentarium, these patients have not only shown improvement in progression free survival (PFS) and response rates (RR) but also overall survival (OS) has improved in both the lines compared with endocrine therapy (ET) alone. Since 2017, in India, the combination of CDK4/6 inhibitors with ET is standard therapy in HR+/HER2- MBC.

Source: European Journal of Cancer - September 30, 2020 Category: Cancer & Oncology Authors: C. Agrawal, D. Doval, A. Agarwal, P. Goyal, S. Baghmar, V. Talwar, U. Batra, S. Goyal, R. Sinha, S. Archana, P. Jain Tags: POSTERS B: Advanced Disease Source Type: research